Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies

Julie Desrivot1, Tim Van Kaem2, Lisa Allamassey3, and Eric Helmer4

Abstract
GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; therefore, the potential for GLPG1205 to interact with enzymes involved in the metabolism of pirfenidone (cytochrome P450 [CYP] 1A2, CYP2C9, 2C19) was evaluated. In vitro experiments indicated weak inhibition of CYP1A2 and moderate but reversible inhibition of CYP2C9 and CYP2C19 by GLPG1205. A phase 1 randomized, double-blind crossover study in 14 healthy males (NCT02623296) evaluated the effect of GLPG1205 100 mg or placebo (once daily for 12 days) on the single-dose pharmacokinetics of a cocktail of CYP1A2, CYP2C9, and CYP2C19 substrates (coadministered on day 13). GLPG1205 had no effect on the exposure of CYP2C9 and CYP1A2 substrates or metabolites; however, a trend toward increased omeprazole (CYP2C19 substrate) exposure was observed. Although considered not clinically relevant, GLPG1205 increased the elimination rate of 5-hydroxyomeprazole (CYP2C19 metabolite) 1.16-fold versus placebo. GLPG1205 had no effect on the elimination of all other substrates or metabolites. GLPG1205 had a favorable safety and tolerability profile. In conclusion, GLPG1205 100 mg once daily does not interact with CYP2C9, CYP2C19, or CYP1A2 to a clinically relevant extent and may be administered concomitantly with drugs metabolized by these enzymes.

Keywords
drug-drug interaction, cytochrome P450, idiopathic pulmonary fibrosis, GLPG1205

GPR84 is a G protein-coupled receptor that is activated by medium-chain fatty acids and is primarily expressed on a number of immune cells such as leukocytes, macrophages, and monocytes.1–3 By stimulating fibrosis, GPR84 may have a deleterious role in fibrotic disease, including pulmonary fibrosis.2 GLPG1205 (9-cyclopropylethynyl-2-[[S]-1-(1,4)dioxan-2-ylmethoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one; compound code G321605; Supplemental Figure 1) is a novel modulator of GPR84 currently under development as a therapy for idiopathic pulmonary fibrosis (IPF). A first-in-human study (NCT01887106) with healthy subjects showed that GLPG1205 had an acceptable safety and tolerability profile, with a maximum tolerated dose of 100 mg once a day.5 In healthy male subjects, GLPG1205 was absorbed with a median time to maximum plasma concentration (tmax) of 4 hours. After once-daily oral dosing for 14 days, a steady-state GLPG1205 plasma concentration was reached by day 10, and the elimination half-life was on average 88.6 hours.4 GLPG1205 50 and 100 mg are currently under phase 2 clinical investigation.

Pirfenidone and nintedanib are currently the only 2 pharmacological options approved for the treatment of IPF.5 In future clinical trials, GLPG1205 may be concomitantly administered with pirfenidone and nintedanib; therefore, it is important to

1 Galapagos, Romainville, France
2 Galapagos, Mechelen, Belgium
3 Alten Belgium, Brussels, Belgium
4 Galapagos Biotech Ltd, Cambridge, UK

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Submitted for publication 16 October 2020; accepted 22 March 2021.

Corresponding Author:
Eric Helmer, PharmD, Galapagos Biotech Limited, Salisbury House, Station Road, Cambridge CB1 2LA, UK
(e-mail: Eric.Helmer@glpg.com)
Julie Desrivôt: current affiliation — Pierre Fabre Médicament, Toulouse, France
Lisa Allamassey: current affiliation — BMS, Braine l’Alleud, Belgium
investigate the potential for GLPG1205 to interact with enzymes involved in the metabolism of each drug. The mechanism of action of pirfenidone is incompletely understood; however, data have shown that pirfenidone attenuates fibroblast proliferation and the production of fibrosis-associated proteins and cytokines and increases biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as transforming growth factor-beta and platelet-derived growth factor.\(^6\) Pirfenidone is mainly metabolized by cytochrome P450 (CYP) 1A2 and, to a lesser degree, CYP2C9 and CYP2C19\(^7,8\); therefore, agents that induce or inhibit these enzymes have the potential to adversely affect exposure to pirfenidone. Nintedanib is a small-molecule tyrosine kinase inhibitor including the receptors platelet-derived growth factor receptor \(\alpha\) and \(\beta\), fibroblast growth factor receptor 1-3, and vascular endothelial growth factor receptor 1-3.\(^9\) Nintedanib is primarily metabolized via hydrolytic ester cleavage and only a minor extent of nintedanib biotransformation involves CYP pathways, predominantly CYP3A4.\(^10,11\) A first-in-human study has shown that GLPG1205 did not induce CYP3A4 based on evaluation of the cortisol:6\(\beta\)-hydroxy cortisol ratio in urine\(^4,12\); therefore, the current studies focused on potential for interactions with pirfenidone, which may be more complex given the involvement of multiple CYP450 enzymes.

The aims of the studies presented in this article were to assess the potential for GLPG1205 to induce/inhibit CYP2C9, CYP2C19, and CYP1A2 in vitro and to clinically assess the effect of multiple doses of GLPG1205 on the pharmacokinetics (PK) of a validated cocktail of substrates\(^13\) for these enzymes.

**Methods**

**In Vitro Studies**

Full details of the methods used in both in vitro studies are detailed in the Supplemental Methods. A brief summary is provided below.

**In Vitro Assessment of CYP1A2 Induction.** Solubility and cytotoxicity experiments were performed prior to incubation of GLPG1205 with cells.

GLPG1205 was incubated with monolayer cultures of fresh human hepatocytes from 3 individual donors for 24 hours (messenger ribonucleic acid [mRNA] analysis) or 48 hours (enzyme activity) at 6 different concentrations: 0.5, 1, 5, 10, 50, and 100 \(\mu\)M (0.19, 0.38, 1.89, 3.78, 18.9, and 37.8 \(\mu\)g/mL, respectively). All incubations contained 0.4% dimethylsulfoxide (DMSO). Incubation with 50 \(\mu\)M omeprazole containing 0.1% DMSO was used as a positive control. Incubations with 0.1% and 0.4% DMSO alone were used as negative controls.

Following a 24-hour incubation, CYP1A2 mRNA was quantified using real-time quantitative reverse transcription polymerase chain reaction.

Following a 48-hour incubation period, an enzymatic assay assessed phenacetin O-deethylase (a CYP1A2 substrate) activity by measuring the CYP1A2-dependent metabolite acetaminophen in supernatants. Acetaminophen was quantified using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).

For enzyme activity measurement, the criteria for data acceptance were considered met if the activity was higher than the limit of quantification of the method and if a successful induction at least equal to 2 times the control activity was obtained for all reference enzyme inducers. GLPG1205 was considered an enzyme inducer if the increase in enzyme activity was \(\geq40\%\) of the response to the positive control. For the mRNA measurement, the in vitro study was considered positive for enzyme induction if incubations with GLPG1205 resulted in a more than 100% (ie, 2-fold) increase in mRNA compared with the vehicle control, and the increase was concentration dependent.\(^14\) A concentration-dependent increase in mRNA of \(<100\%\) was considered a negative finding when the increase in mRNA was less than 20% of the response of the positive control.

**In Vitro Assessment of CYP2C9, CYP2C19, and CYP1A2 Inhibition.** Solubility experiments were performed prior to incubation of GLPG1205 with cells.

Inhibition of the biotransformation of CYP-specific substrates by GLPG1205 was studied using human liver microsomes. Incubation was performed at 37°C with the following conditions: \(n = 3\) for all assays; 0.1 M phosphate buffer (pH 7.4), the cofactor nicotinamide adenine dinucleotide phosphate (NADPH) incubated at 2 mM, the CYP-specific substrate incubated at 1 nonsaturating concentration, and GLPG1205. Additional incubation was performed with (1) a 30-minute preincubation step of GLPG1205 with microsomes before the addition of the cofactor NADPH and CYP substrate; and (2) a 30-minute preincubation step of GLPG1205 with microsomes and the cofactor NADPH, before the addition of the CYP substrate. GLPG1205 was tested at 6 concentrations: 0.5, 1, 5, 10, 50, and 100 \(\mu\)M (0.19, 0.38, 1.89, 3.78, 18.9, and 37.8 \(\mu\)g/mL, respectively), for each condition. The CYP-specific substrates were incubated per the above conditions at the following concentrations: tolbutamide, 200 \(\mu\)M, CYP2C9 substrate; S-mephenytin, 60 \(\mu\)M, CYP2C19 substrate; phenacetin, 40 \(\mu\)M, CYP1A2 substrate. Reference inhibitors were used to validate the inhibition screening assays for each enzyme and were incubated in parallel: sulfaphenazole (5 \(\mu\)M, CYP2C9 inhibitor); tranylcypromine (40 \(\mu\)M,
Drug-Drug Interaction Study

Study Design. This was a phase 1 single-center, randomized, double-blind, placebo-controlled crossover drug-drug interaction study (ClinicalTrials.gov number NCT02623296). The objectives of the study were to evaluate the effect of multiple oral doses of GLPG1205 on the single-dose PK of a cocktail of CYP450 substrates and to evaluate the safety and tolerability of multiple doses of GLPG1205 administered with or without a cocktail of CYP450 substrates in healthy male subjects. The cocktail of CYP450 substrates contained CYP2C9 (warfarin 10 mg in tablet form), CYP2C19 (omeprazole 20 mg in capsule form), and CYP1A2 (caffeine 100 mg as an oral solution) substrates. Covariates that could impact GLPG1205 disposition are currently not known; therefore, to minimize variability that covariates could generate on the single-dose PK of a cocktail of CYP450 substrates and their metabolites in plasma. In each treatment period, blood samples were collected by venipuncture in the arm predose on days 7, 9, 10, and 13 and on day 13 at 1, 2, 4, 6, 8, 12, 24 (day 14), 48 (day 15), 96 (day 17), and 144 (day 19) hours postdose for PK analysis. For treatment period 2, an additional blood sample was also taken at 168 hours (day 20; follow-up visit) postdose. Samples collected on days 7, 9, and 10 were for GLPG1205 analysis only. Blood samples of 2 mL were collected for the determination of GLPG1205 in plasma, and of 9 mL for the determination of CYP450 substrates and their metabolites. After collection, blood samples were immediately chilled using an ice bath. Within 30 minutes of collection, samples were separated by centrifugation at 1500 g for 10 minutes at 4°C. For GLPG1205, ≥250 μL of plasma was transferred into 2.0-mL polypropylene tubes and stored at −20°C or below immediately after centrifugation at the clinical center until shipment to analysis centers. For CYP450 substrates, 500 μL of plasma was transferred to 2.0-mL polypropylene tubes. Plasma samples were stored at −20°C or below (omeprazole/5-hydroxyomeprazole) or −70°C or below (S-warfarin/(S)-7-hydroxywarfarin and caffeine/paraxanthine) immediately after centrifugation at the clinical center until shipment to analysis centers. All samples were shipped on dry ice to analysis centers.

CYP2C19 inhibitor); and furafylline (10 μM, CYP1A2 inhibitor).

The test concentrations were chosen based on the limit of solubility of GLPG1205 in the experimental conditions and were selected to be in close proximity to the maximum observed plasma concentration (Cmax) determined at steady state in the first-in-human study following multiple doses of 100 mg once a day. Further details of the assays used for each CYP substrate are reported in the Supplemental Methods. Metabolites of the CYP-specific substrates (acetaminophen for CYP1A2, hydroxylbutamide for CYP2C9, hydroxymephenytoin for CYP2C19) were quantified using LC-MS/MS.

Enzymatic activity in the presence of GLPG1205 was expressed as a percentage of the control activity obtained with the vehicle only (ie, without GLPG1205 or reference inhibitor). Decreases in activity of less than 20% were not considered clinically relevant.
Repertitive freeze-thaw cycles were avoided to maintain the integrity of samples. Plasma concentrations were measured using LC-MS/MS; further details can be found in the Supplemental Methods. Pharmacokinetic calculations were performed by SGS LSS using Phoenix WinNonLin 6.2 or higher (Pharsight Corporation, Palo Alto, California). The PK parameters determined for GLPG1205, S-warfarin/(S)-7-hydroxyswarfarin, omeprazole/5-hydroxyomeprazole, and caffeine/paraxanthine included C\text{max}, t\text{max}, area under the plasma concentration-time curve (AUC) from time zero until the time corresponding to the last observed quantifiable concentration (AUC_{0–\text{inf}}), AUC from time zero to infinity (AUC_{0–t}), apparent terminal half-life (t_{1/2},\text{z}), and metabolite-over-parent ratio (R). Values below the quantification limit were imputed by 0 for the calculation of descriptive statistics except for geometric mean and geometric coefficient of variation (CV), for which it was imputed by half the lower limit of quantification.

**Safety Assessments.** The safety assessment was based on adverse events (AEs), vital signs, 12-lead electrocardiogram (ECG), physical examinations, and safety laboratory tests. AEs were monitored for the duration of the study. All safety assessments were undertaken at the screening visit, on days 13 and 14, and at the follow-up visit. In addition, safety assessments were undertaken on day 1 (vital signs, 12-lead ECG, and clinical laboratory tests) and day 7 (physical examination, vital signs, and clinical laboratory tests).

**Statistical Analysis.** This is a pilot phase 1 study involving 14 subjects, and strict statistical criteria were not used to determine the sample size. The number of subjects included in this study gave reasonable precision around the estimates derived for the safety and PK evaluation. The PK population comprised all subjects who were exposed to GLPG1205/placebo and who had available and evaluable data. The safety population comprised all randomized subjects who received at least 1 dose of study drug.

An analysis of variance (ANOVA) with treatment, treatment period, and sequence as fixed effects and subject as a random effect was performed on natural log-transformed PK parameters (R, C_{\text{max}}, AUC_{0–\text{inf}}, AUC_{0–t}, and t_{1/2,\text{z}}) of CYP450 substrates and their metabolites on day 13. The treatment effect for t_{\text{max}} was assessed using the nonparametric Wilcoxon’s signed rank test. Point estimates were calculated as the geometric mean of the individual ratios for each parameter for treatment A (GLPG1205 + CYP450 substrates) relative to treatment B (placebo + CYP450 substrates) and expressed as fold difference. The 90% confidence interval of the point estimate was calculated using the mean square error of the ANOVA. For GLPG1205, time to reach steady state was assessed by visual inspection of the trough plasma concentrations on days 7, 9, 10, and 13 (predose and 24 hours postdose).

**Results**

**In Vitro Studies**

**In Vitro Assessment of CYP1A2 Induction.** The limit of solubility of GLPG1205 in culture medium for incubations was 100 \(\mu\)M with a final DMSO percentage equal to 0.4%. According to morphological observations and neutral red uptake, GLPG1205 was found not cytotoxic over the range of 0-50 \(\mu\)M and cytotoxic at 100 \(\mu\)M.

In the presence of 50 \(\mu\)M omeprazole (positive control), phenacetin O-deethylase activity was increased by a factor of 53.9, 10.7, and 35.2 in the 3 hepatocyte batches (Supplemental Table 2). Therefore, the experiment met the validation criteria. All increases in CYP1A2 activity following incubation with GLPG1205 were lower than 40% of the positive control (omeprazole) and did not exceed 2-fold compared with the negative control (0.4% DMSO; Supplemental Table 2).

In the presence of 50 \(\mu\)M omeprazole (positive control), CYP1A2 mRNA was increased by a factor of 341, 403, and 85.9 in the 3 hepatocyte batches (Supplemental Table 3). In the presence of GLPG1205 (0.1-50 \(\mu\)M), 1 hepatocyte batch (HEP220794) showed no significant increase in CYP1A2 mRNA, with a maximum 1.60-fold induction at 5 \(\mu\)M compared with vehicle control (Supplemental Table 3). In the other 2 hepatocyte batches, an increase in CYP1A2 mRNA expression (greater than 100% when compared with the vehicle control) was observed at the low concentrations, with a maximum 6-fold induction at 1 \(\mu\)M GLPG1205 and lower fold induction observed at 5 to 50 \(\mu\)M GLPG1205 (Supplemental Table 3).

**In Vitro Assessment of CYP2C9, CYP2C19, and CYP1A2 Inhibition**

All 3 experiments met the validation criteria with the percentage of inhibition obtained for the reference inhibitor was equal or greater than 50%.

Results demonstrated a moderate and reversible inhibition of CYP2C9 and CYP2C19 by GLP1205 50-100 \(\mu\)M (Supplemental Figures 2 and 3). Inhibition of CYP2C9 ranged between 49.0% and 56.9% in the presence of GLPG1205 50-100 \(\mu\)M without preincubation with similar percentages observed following a 30-minute preincubation step with and without NADPH (Supplemental Figure 2). Similarly, CYP2C19 inhibition ranged between 44.2% and 49.3% in the presence of GLPG1205 50-100 \(\mu\)M without preincubation, with similar percentages observed in both preincubation...
Subjects screened
N = 53

Non-randomized subjects:
Did not meet inclusion/exclusion criteria: n = 21
Cohort/group cancelled: n = 12
Withdrawal by subject: n = 6

Randomized and treated
n = 14

Placebo
n = 7

GLPG1205
n = 7

Completed
n = 7

Completed
n = 7

Figure 1. Flow chart to show details of subjects screened, randomized, and allocated to each treatment arm in the DDI study. DDI, drug-drug interaction.

Table 1. Demographics of Subjects in the DDI Study at Baseline

|                      | All Subjects (n = 14) |
|----------------------|-----------------------|
| Age, years (Mean (SE)) | 40.6 (1.97)          |
| Weight, kg (Mean (SE)) | 79.6 (2.79)          |
| BMI, kg/m² (Mean (SE)) | 24.8 (0.70)          |
| Race, n (%)           |                       |
| White                 | 13 (92.9)             |
| Unknown               | 1 (7.1)               |
| Sex, n (%)            |                       |
| Male                  | 14 (100)              |

BMI, body mass index; SE, standard error.

step conditions (with/without NADPH; Supplemental Figure 3). Weak in vitro inhibition of CYP1A2 was observed with GLPG1205 50-100 μM. CYP1A2 inhibition ranged between 20.4% and 38.0% in the presence of GLPG1205 50-100 μM, with 52.9% inhibition observed with GLPG1205 100 μM following a 30-minute preincubation with NADPH (Supplemental Figure 4). The IC₅₀ for inhibition of CYP2C9, CYP2C19, and CYP1A2 was estimated to be approximately 50 μM, ≥50 μM, and ≥100 μM, respectively.

Drug-Drug Interaction Study

Study Disposition and Demographics. Fourteen healthy male subjects (median age, 41.5 years) were randomized to 1 of 2 treatment sequences (Table 1 and Figure 1).

All randomized subjects completed the study. The study was conducted from September 24, 2015, until January 27, 2016.

PK Profile: GLPG1205. The PK parameters for GLPG1205 following 12 days of administration of GLPG1205 100 mg once a day are shown in Table 2. Tₘₘₙ was reached at 2 hours, with an apparent mean half-life of 74.1 hours (Table 2). There were no statistically significant differences in the trough GLPG1205 plasma concentrations from day 9 to day 13, indicating steady state was reached by day 9 (ie, after 8 dosing days). In-depth results on GLPG1205 PK parameters have previously been reported.⁴

PK Profiles: (S)-Warfarin and Its Metabolite (S)-7-Hydroxywarfarin (CYP2C9). The plasma concentration-versus-time profiles were similar when (S)-warfarin was
administered with GLPG1205 or placebo (Figure 2A). The exposure of (S)-warfarin was not affected when coadministered with GLPG1205 versus placebo, as the geometric mean ratio (90% confidence interval [CI]) for $C_{\text{max}}$, $\text{AUC}_{0-\text{t}}$, $\text{AUC}_{0-\infty}$, and $t_{1/2,\lambda z}$ were all within the 0.80-1.25 fold difference range (Table 3A). The elimination phases were similar in both treatment groups, with (S)-warfarin concentrations still quantifiable at the 144-hour postdose measurement in all subjects (Figure 2A). The PK profile of (S)-7-hydroxywarfarin...
was not affected by GLPG1205 compared with placebo (Table 3B). (S)-7-hydroxywarfarin plasma concentrations were still quantifiable at 144 hours postdose in 12 of 14 subjects in each treatment group. The metabolite:parent ratios for (S)-7-hydroxywarfarin:(S)-warfarin were similar when placebo or GLPG1205 was coadministered (0.156 and 0.158, respectively; Table 3B). (S)-7-hydroxywarfarin plasma concentrations were still quantifiable 12 hours postdose for 7 of 14 subjects in the placebo group and 8 of 14 subjects in the GLPG1205 group.

PK Profiles: Omeprazole and Its Metabolite 5-Hydroxyomeprazole (CYP2C19). The maximal mean plasma concentrations of omeprazole was reached rapidly in both treatment groups, although there was some deviation in the elimination rates (Figure 2B). The exposure (AUC0-t, AUC0-inf, and Cmax) of omeprazole when coadministered with GLPG1205 was increased 1.28- to 1.36-fold versus placebo, with an upper limit of the 90% CI of 1.49-1.65 (Table 4A). Between-subject variability in omeprazole Cmax and AUC was high in both treatment groups (CV% between 69.3% and 83.9% with placebo and between 54.4% and 67.1% with GLPG1205; Table 4A). Omeprazole plasma concentrations were still quantifiable 12 hours postdose for 5 of 14 subjects in the placebo group and 3 of 14 subjects in the GLPG1205 group. The results indicate coadministration of either placebo or GLPG1205 had no effect on the clearance of 5-hydroxyomeprazole (Table 4B). The 5-hydroxyomeprazole plasma concentrations were still quantifiable 12 hours postdose for 7 of 14 subjects in the placebo group and 8 of 14 subjects in the GLPG1205 group.

PK Profiles: Caffeine and Its Metabolite Paraxanthine (CYP1A2). Predose caffeine plasma concentrations were above the lower limit of quantification (>100 ng/mL) and at a significant level (>5% Cmax) for 2 subjects in each treatment group. Caffeine was also quantifiable in all subjects at the first sampling point (15 minutes postdose). The maximal mean plasma concentration for caffeine was rapidly reached and similar in both treatment groups (Figure 2C). The exposure of caffeine was similar in the presence of placebo or GLPG1205 (Table 5A). For caffeine, the elimination phase was monophasic and superimposed in both treatment groups (Figure 2C). Caffeine plasma concentrations were still quantifiable 24 hours postdose for 6 of 14 subjects in both treatment groups. The PK profile of paraxanthine was similar in the presence of
placebo or GLPG1205; overall PK parameters were similar between treatment groups, and the 90% CIs were close to or within the 0.80- to 1.25-fold range (Table 5B). Paraxanthine plasma concentrations were still quantifiable 24 hours postdose for 10 and 7 of 14 subjects in the placebo and GLPG1205 groups, respectively. The metabolite:parent ratio for paraxanthine:caffeine was similar following coadministration with placebo or GLPG1205 (Table 5B).

Safety and Tolerability Profile. With placebo alone, 6 subjects reported a treatment-emergent AE (TEAE), and with GLPG1205 alone, 9 subjects reported a TEAE (Table 6A). The most commonly reported TEAEs with GLPG1205 or placebo alone were headache (GLPG1205, n = 5; placebo, n = 3), gastroenteritis (GLPG1205, n = 1; placebo, n = 1), and disturbance in attention (GLPG1205, n = 2). All cases of headache and disturbance in attention were considered treatment related. In both GLPG1205 plus CYP450 and placebo plus CYP450 substrate treatment groups, 3 subjects reported a TEAE (Table 6B). The most commonly reported TEAE during CYP450 substrate administration was headache (GLPG1205 plus CYP450 substrates, n = 1; placebo plus CYP450 substrates, n = 1). All TEAEs reported were mild in intensity except for moderate headache (placebo alone, n = 1), moderate presyncope (GLPG1205 alone, n = 1), and moderate oropharyngeal pain (GLPG1205 plus CYP450 substrates, n = 1). No clinically significant trends or abnormalities were detected with laboratory safety tests, ECG, vital signs, or physical examination. There were no deaths or serious AEs during the study.

Discussion

As part of the development of GLPG1205 for the treatment of IPF, we investigated the potential of GLPG1205 to interact with other drugs. As GLPG1205 may be administered with pirfenidone in future clinical trials, a special focus was made on the CYP450 enzymes

---

**Table 4. PK Parameters for (A) Omeprazole and (B) 5-Hydroxyomeprazole**

A

| Comparison | Placebo + Omeprazole CYP2C19 Substrate, n = 14 | GLPG1205 100 mg Once a Day + Omeprazole CYP2C19 Substrate, n = 14 | Comparison\(^a\) PE (90% CI) or P |
|------------|-----------------------------------------------|-------------------------------------------------|---------------------------------|
| \(C_{\text{max}}\) (\(\mu g/mL\)) | 0.219 (69.3) | 0.270 (54.4) | 1.30 (1.03-1.65) |
| \(t_{\text{max}}\) (h) | 3.0 (2.0-5.0) | 2.0 (1.0-5.0) | \(P = 0.828\) |
| \(AUC_{0-c}\) (\(\mu g\cdot h/mL\)) | 0.486 (83.9) | 0.563 (63.5) | 1.28 (1.10-1.49) |
| \(AUC_{0-t}\) (\(\mu g\cdot h/mL\)) | 0.520 (78.5)\(^n = 13\) | 0.548 (67.1)\(^n = 13\) | 1.36 (1.18-1.58) |
| \(t_{1/2, z}\) (h) | 0.815 (30.7)\(^n = 13\) | 0.825 (24.7)\(^n = 13\) | 1.09 (0.97-1.22) |

B

| Comparison | Placebo + Omeprazole CYP2C19 Substrate, n = 14 | GLPG1205 100 mg Once a Day + Omeprazole CYP2C19 Substrate, n = 14 | Comparison\(^a\) PE (90% CI) or P |
|------------|-----------------------------------------------|-------------------------------------------------|---------------------------------|
| \(C_{\text{max}}\) (\(\mu g/mL\)) | 0.149 (26.7) | 0.162 (38.0) | 1.05 (0.88-1.25) |
| \(t_{\text{max}}\) (h) | 3.0 (2.0-5.0) | 2.5 (2.0-6.0) | \(P = 0.992\) |
| \(AUC_{0-c}\) (\(\mu g\cdot h/mL\)) | 0.383 (21.6) | 0.414 (22.7) | 1.08 (0.96-1.21) |
| \(AUC_{0-t}\) (\(\mu g\cdot h/mL\)) | 0.388 (20.9) | 0.422 (21.7) | 1.08 (0.98-1.20) |
| \(t_{1/2, z}\) (h) | 1.18 (22.1) | 1.37 (23.7) | 1.16 (1.04-1.30) |
| \(R_{\text{AUC}_{0-c}}\) | 1.06 (76.7)\(^n = 13\) | 0.889 (68.4) | 0.84 (0.79-0.89) |
| \(R_{\text{AUC}_{0-t}}\) | 0.983 (69.7)\(^n = 13\) | 0.958 (64.2) | 0.83 (0.77-0.89) |

ANOVA, analysis of variance; AUC, area under the curve; AUC\(_{0-c}\), from time zero until time corresponding to the last observed quantifiable concentration; AUC\(_{0-t}\), from time zero to infinity; CI, confidence interval; \(C_{\text{max}}\), plasma concentration; CV, coefficient of variation; PE, point estimate; PK, pharmacokinetics; \(R\), metabolite-over-parent ratio; \(t_{1/2, z}\), apparent terminal half-life; \(t_{\text{max}}\), time occurrence of \(C_{\text{max}}\).

Values are arithmetic mean (CV%), except for \(t_{\text{max}}\), which is median (min-max), and for \(R_{\text{AUC}_{0-c}}\) and \(R_{\text{AUC}_{0-t}}\), which are geometric mean (geometric CV%).

\(^a\)PE and 90% CI of the least-squares geometric means ratio of GLPG1205 relative to placebo (ANOVA); \(P\) value from Wilcoxon’s signed rank test for \(t_{\text{max}}\).
involved in the metabolism of pirfenidone (CYP1A2, CYP2C9, and CYP2C19).\textsuperscript{7,8}

Results of the in vitro studies indicated there was weak inhibition of CYP1A2 (with no interpretation about reversibility) and moderate but reversible inhibition of CYP2C9 and CYP2C19 by GLPG1205. The estimated IC\textsubscript{50} values for inhibition of CYP2C9/2C19 (\geq 50 \mu M, equivalent to 18.9 \mu g/mL) and CYP1A2 (\geq 100 \mu M, equivalent to 37.8 \mu g/mL) observed in the current study are approximately 5- to 10-fold greater than the C\textsubscript{max} of 3.91 \mu g/mL reached following multiple doses of GLPG1205 100 mg once a day (the maximum tolerated dose) in the first-in-human study characterizing PK properties of GLPG1205.\textsuperscript{4} The in vitro assessment of CYP1A2 induction revealed that GLPG1205 increased CYP1A2 mRNA expression more than 100% compared with the vehicle control. On the basis of these results and given that the cumulative impact of weak/moderate effects on multiple CYP450 enzymes is difficult to predict, it was necessary to ensure GLPG1205 did not interfere with the pirfenidone metabolism pathways by conducting a clinical study.

The PK properties of GLPG1205 100 mg once a day observed in the current study were similar to those previously reported in a first-in-human study, with rapid absorption, a long apparent terminal elimination half-life, and similar steady-state plasma concentrations.\textsuperscript{4} Comparison of the results from both studies demonstrated that subjects in the current drug-drug interaction study were adequately exposed to GLPG1205 under steady-state conditions at the projected (or maximum tolerated) 100-mg once-a-day dose.

The coadministration of CYP450 substrates on day 13, following 12 days of GLPG1205 100-mg once-a-day dosing alone, resulted in no significant effect on the exposure of the CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP1A2 (caffeine) substrates or the PK profiles of their metabolites. Despite an increase in omeprazole exposure, there was no increase in the elimination rate of omeprazole. The elimination rate of 5-hydroxyomeprazole was 1.16-fold higher with GLPG1205 versus placebo, but this was not considered clinically relevant because of the high between-subject variability of omeprazole exposure (54%-84%), and there was only a slight impact on the parent:metabolite ratio for omeprazole:5-hydroxyomeprazole. Overall, this study confirmed that GLPG1205 does not interact with CYP2C9, CYP2C19,
### Table 6. Incidence of Adverse Events With (A) Placebo or GLPG1205 Alone and (B) Placebo or GLPG1205 Plus CYP450 Substrates

#### A

| System Organ Class          | Placebo, GLPG1205 100 mg Once a Day, n (%) | GLPG1205 100 mg Once a Day, n = 14 |
|-----------------------------|--------------------------------------------|-----------------------------------|
| Preferred Term, n (%)       |                                             |                                   |
| Any TEAE                    | 6 (42.9)                                   | 9 (64.3)                          |
| Nervous system disorders    |                                            |                                   |
| Headache                    | 3 (21.4)                                   | 8 (57.1)                          |
| Disturbance in attention    | 0                                           | 2 (14.3)                          |
| Paresthesia                 | 0                                           | 1 (7.1)                           |
| Presyncope                  | 0                                           | 1 (7.1)                           |
| General disorders and       |                                            |                                   |
| administration-site         |                                            |                                   |
| conditions                 |                                            |                                   |
| Fatigue                     | 0                                           | 1 (7.1)                           |
| Musculoskeletal and         |                                            |                                   |
| connective tissue disorders  | 1 (7.1)                                    | 1 (7.1)                           |
| Myalgia                     | 0                                           | 1 (7.1)                           |
| Back pain                   | 1 (7.1)                                    | 0                                 |
| Eye disorders               |                                            |                                   |
| Lacrimation increased       | 0                                           | 1 (7.1)                           |
| Vision blurred              | 1 (7.1)                                    | 0                                 |
| Gastrointestinal disorders  |                                            |                                   |
| Flatulence                  | 0                                           | 1 (7.1)                           |
| Infections and infestations |                                            |                                   |
| Gastroenteritis             | 1 (7.1)                                    | 1 (7.1)                           |
| Nasopharyngitis             | 1 (7.1)                                    | 0                                 |
| Skin and subcutaneous      |                                            |                                   |
| tissue disorders            |                                            |                                   |
| Hyperhidrosis               | 1 (7.1)                                    | 0                                 |
| Rash                        | 1 (7.1)                                    | 0                                 |
| Respiratory, thoracic, and  |                                            |                                   |
| mediastinal disorders       |                                            |                                   |
| Oropharyngeal pain          | 0                                           | 1 (7.1)                           |
| Vascular disorders          | 0                                           | 1 (7.1)                           |
| Flushing                    | 0                                           | 1 (7.1)                           |

#### B

| System Organ Class          | Placebo + CYP450 Substrates, n = 14 | GLPG1205 100 mg Once a Day + CYP450 Substrates, n = 14 |
|-----------------------------|-------------------------------------|--------------------------------------------------|
| Preferred Term, n (%)       |                                     |                                                  |
| Any TEAE                    | 3 (21.4)                            | 3 (21.4)                                         |
| Nervous system disorders    | 1 (7.1)                             | 1 (7.1)                                          |
| Headache                    | 1 (7.1)                             | 1 (7.1)                                          |

(Continued)

**Table 6. (Continued)**

| System Organ Class          | Placebo + CYP450 Substrates, n = 14 | GLPG1205 100 mg Once a Day + CYP450 Substrates, n = 14 |
|-----------------------------|-------------------------------------|--------------------------------------------------|
| Preferred Term, n (%)       |                                     |                                                  |
| General disorders and       |                                     |                                                  |
| administration-site         |                                     |                                                  |
| conditions                 |                                     |                                                  |
| Influenza-like illness      | 1 (7.1)                             | 0                                                 |
| Pain                       | 1 (7.1)                             | 0                                                 |
| Musculoskeletal and         |                                     |                                                  |
| connective tissue disorders  |                                     |                                                  |
| Myalgia                     | 0                                   | 1 (7.1)                                           |
| Gastrointestinal disorders  | 1 (7.1)                             | 0                                                 |
| Nausea                      | 1 (7.1)                             | 0                                                 |
| Respiratory, thoracic, and  |                                     |                                                  |
| mediastinal disorders       |                                     |                                                  |
| Oropharyngeal pain          | 0                                   | 1 (7.1)                                           |

TEAE, treatment-emergent adverse event.

or CYP1A2 in humans to a clinically relevant extent and therefore provides reassurance that GLPG1205 can be administered with pirfenidone in future clinical trials.

Multiple oral doses of GLPG1205 100 mg once a day administered with or without CYP450 substrates had safety and tolerability profiles comparable to the first-in-human study,4 with no new safety signals observed in the current study.

Some limitations must be acknowledged. There was a small sample size and homogeneity of subjects in the clinical study; however, these were appropriate for a phase 1 study.

### Conclusions

GLPG1205 does not interact with CYP2C9, CYP2C19, and CYP1A2 in humans to a clinically relevant extent, and therefore, GLPG1205 may be administered concomitantly with drugs that are metabolized by these enzymes.

### Acknowledgments

The authors thank Lien Gheyle (SGS Life Science Services) for her role as principal investigator of the study. Medical writing support for the development of this article, under the direction of the authors, was provided by Zoe Schafer, Jane Murphy, and Emily Fisher of Ashfield MedComms, an Ashfield Health company, and funded by Galapagos.
Conflicts of Interest
T.V.K. and E.H. are employees of Galapagos. J.D. and L.A. are former employees of Galapagos. No COIs were reported by spouses/partners of the authors.

Funding
The study and writing/editorial support were funded by Galapagos, Mechelen, Belgium.

Author Contributions
All authors provided substantial contributions to the design or the acquisition, analysis, or interpretation of data. Authors critically reviewed the article for important intellectual content. All authors read and approved the final version of the article.

Data Availability Statement
Data will not be shared.

References
1. Wang J, Wu X, Simonavicius N, Tian H, Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006;281(45):34457–34464.

2. Gagnon L, Leduc M, Thibodeau JF, et al. A Newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am J Pathol. 2018;188(5):1132–1148.

3. Suzuki M, Takaishi S, Nagasaki M, et al. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chemistry. 2013;288(15):10684–10691.

4. Timmis H, Van Kaem T, Desrivot J, et al. GLPG1205, a GPR84 modulator: safety, pharmacokinetics, and pharmacodynamics in healthy subjects. Clin Pharmacol Drug Dev. In press. https://doi.org/10.1002/cpdd955

5. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015;191(3):252-254.

6. Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs. 2010;19(2):275-283.

7. Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Raguenneau-Majlessi I. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab Dispos. 2018;46(6):835-845.

8. Yu J, Ritchie TK, Zhou Z, Raguenneau-Majlessi I. Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the Food and Drug Administration in 2014. Drug Metab Dispos. 2016;44(1):83-101.

9. Wollin L. Interpretation of data from studies of effects of nintedanib on surfactant protein-D expression in human lung epithelial cells. Palm Pharmacol Ther. 2015;33:15-16. https://www.sciencedirect.com/science/article/abs/pii/S1094553915000620

10. Filppula AM, Mustonen TM, Backman JT. In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug-drug interactions. Basic Clin Pharmacol Toxicol. 2018;123(6):739-748.

11. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41(4):297-311.

12. Sychev DA, Ashraf GM, Sivistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther. 2018;12:1147-1156. https://www.dovepress.com/the-cytochrome-p450-isoenzyme-and-some-new-opportunities-for-the-prediction-of-negative-drug-interactions-peer-reviewed-article-DDDT

13. Turpault S, Brian W, Van Horn R, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928-935.

14. Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos. 2008;36(1):137-145.

Supplemental Information
Additional supplemental information can be found by clicking the Supplements link in the PDF toolbar or the Supplemental Information section at the end of web-based version of this article.